Return on Assets (ROA)
since 2005
Calculation
Vertex Pharmaceuticals Inc., ROA, long-term trends, calculation
| ROA | = | 100 | × | Net income (loss)1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 15.42% | = | 100 | × | 3,953,200) | ÷ | 25,643,000) |
| Dec 31, 2024 | -2.38% | = | 100 | × | (535,600) | ÷ | 22,533,200) |
| Dec 31, 2023 | 15.92% | = | 100 | × | 3,619,600) | ÷ | 22,730,200) |
| Dec 31, 2022 | 18.30% | = | 100 | × | 3,322,000) | ÷ | 18,150,900) |
| Dec 31, 2021 | 17.44% | = | 100 | × | 2,342,100) | ÷ | 13,432,500) |
| Dec 31, 2020 | 23.07% | = | 100 | × | 2,711,647) | ÷ | 11,751,808) |
| Dec 31, 2019 | 14.15% | = | 100 | × | 1,176,810) | ÷ | 8,318,465) |
| Dec 31, 2018 | 33.57% | = | 100 | × | 2,096,896) | ÷ | 6,245,898) |
| Dec 31, 2017 | 7.43% | = | 100 | × | 263,484) | ÷ | 3,546,014) |
| Dec 31, 2016 | -3.87% | = | 100 | × | (112,052) | ÷ | 2,896,787) |
| Dec 31, 2015 | -22.26% | = | 100 | × | (556,334) | ÷ | 2,498,875) |
| Dec 31, 2014 | -31.63% | = | 100 | × | (738,555) | ÷ | 2,334,679) |
| Dec 31, 2013 | -19.19% | = | 100 | × | (445,028) | ÷ | 2,319,041) |
| Dec 31, 2012 | -3.88% | = | 100 | × | (107,032) | ÷ | 2,759,288) |
| Dec 31, 2011 | 1.34% | = | 100 | × | 29,574) | ÷ | 2,204,280) |
| Dec 31, 2010 | -43.74% | = | 100 | × | (754,626) | ÷ | 1,725,446) |
| Dec 31, 2009 | -32.84% | = | 100 | × | (642,178) | ÷ | 1,955,488) |
| Dec 31, 2008 | -46.90% | = | 100 | × | (459,851) | ÷ | 980,479) |
| Dec 31, 2007 | -65.05% | = | 100 | × | (391,279) | ÷ | 601,477) |
| Dec 31, 2006 | -22.45% | = | 100 | × | (206,891) | ÷ | 921,579) |
| Dec 31, 2005 | -37.05% | = | 100 | × | (203,417) | ÷ | 548,998) |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
The Return on Assets (ROA) exhibited significant volatility over the analyzed period, spanning from 2005 to 2025. Initially, the ROA was negative, indicating the company generated insufficient income relative to its assets. A period of improvement followed, culminating in positive ROA values, before experiencing another period of fluctuation, including a substantial negative value in 2023, and a return to positive values in the final year.
- Initial Period (2005-2009)
- From 2005 through 2009, the ROA consistently remained negative, ranging from -65.05% to -32.84%. The magnitude of the negative ROA decreased over this period, but the company consistently failed to generate positive returns from its asset base. The most negative ROA occurred in 2007, at -65.05%, suggesting a particularly challenging year for asset utilization and profitability.
- Transition and Initial Improvement (2010-2012)
- The year 2010 saw a continuation of negative ROA, at -43.74%. However, 2011 marked a turning point, with the ROA becoming positive at 1.34%. This positive trend was short-lived, as the ROA reverted to negative territory in 2012, reaching -3.88%. This suggests early signs of improved performance were not sustained.
- Volatility and Significant Growth (2013-2019)
- The period from 2013 to 2019 was characterized by substantial fluctuations in ROA. Negative ROA values were observed in 2013, 2014, and 2015, ranging from -31.63% to -22.26%. A significant positive shift occurred in 2017, with an ROA of 7.43%, followed by an exceptional increase in 2018, reaching 33.57%. While the ROA decreased in subsequent years, it remained positive, ranging from 14.15% in 2019 to 23.07% in 2020.
- Recent Performance (2020-2025)
- From 2020 to 2022, the ROA remained relatively stable, fluctuating between 17.44% and 18.30%. However, 2023 witnessed a dramatic decline, resulting in a negative ROA of -2.38%. The ROA recovered in 2024, reaching 15.42%, indicating a potential rebound in asset utilization and profitability. The final year observed, 2025, shows a ROA of 15.42%, consistent with the previous year.
Overall, the ROA demonstrates a pattern of initial losses, followed by periods of improvement and volatility. The substantial increase in ROA observed in 2018 and 2019 suggests a period of significant operational efficiency or a change in asset allocation. The sharp decline in 2023 warrants further investigation to determine the underlying causes and assess the sustainability of the subsequent recovery.
AI Ask an analyst for more
Comparison to Competitors
Vertex Pharmaceuticals Inc., ROA, long-term trends, comparison to competitors
| Vertex Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 15.42% | 3.15% | 8.51% | 7.83% | 4.33% | 18.35% | 14.42% | 13.46% | 13.34% | 3.73% | 11.11% | 6.08% |
| Dec 31, 2024 | -2.38% | 3.17% | 4.45% | -9.66% | 5.03% | 13.45% | 0.81% | 7.81% | 14.62% | 3.76% | 11.69% | 6.51% |
| Dec 31, 2023 | 15.92% | 3.61% | 6.91% | 8.43% | 5.64% | 8.19% | 9.12% | 20.98% | 0.34% | 0.94% | 11.95% | 6.07% |
| Dec 31, 2022 | 18.30% | 8.53% | 10.06% | 6.53% | 8.55% | 12.62% | 7.27% | 9.57% | 13.30% | 15.91% | 14.85% | 7.15% |
| Dec 31, 2021 | 17.44% | 7.88% | 9.63% | 6.40% | 7.73% | 11.44% | 9.16% | 11.47% | 12.35% | 12.11% | 31.75% | 8.12% |
| Dec 31, 2020 | 23.07% | 3.07% | 11.54% | -7.61% | 4.79% | 13.28% | 0.18% | 8.41% | 7.72% | 6.23% | 20.47% | 9.23% |
| Dec 31, 2019 | 14.15% | 8.84% | 13.13% | 2.65% | 4.85% | 21.17% | 8.74% | 9.59% | 11.66% | 9.72% | 14.29% | 6.33% |
| Dec 31, 2018 | 33.57% | 9.58% | 12.64% | 14.06% | 5.54% | 7.36% | 8.57% | 10.00% | 7.53% | 7.00% | 20.83% | 5.22% |
| Dec 31, 2017 | 7.43% | 7.50% | 2.48% | 3.00% | 5.34% | -0.45% | 6.58% | 0.83% | 2.72% | 12.40% | 13.67% | 3.93% |
| Dec 31, 2016 | -3.87% | 9.01% | 9.95% | 13.22% | 5.64% | 7.05% | 23.70% | 11.71% | 4.11% | 4.20% | 12.84% | 4.40% |
| Dec 31, 2015 | -22.26% | 9.70% | 9.69% | 4.93% | 6.96% | 6.77% | 34.93% | 11.55% | 4.36% | 4.16% | 11.34% | 4.83% |
| Dec 31, 2014 | -31.63% | 6.44% | 7.47% | 5.94% | 7.02% | 6.43% | 34.91% | 12.45% | 12.12% | 5.40% | 8.99% | 4.42% |
| Dec 31, 2013 | -19.19% | 14.14% | 7.68% | 6.64% | 7.77% | 13.29% | 13.67% | 10.42% | 4.17% | 12.78% | 14.38% | 4.00% |
| Dec 31, 2012 | -3.88% | 19.53% | 8.00% | 5.46% | 7.26% | 11.89% | 12.20% | 8.94% | 5.81% | 7.84% | 36.06% | 4.29% |
| Dec 31, 2011 | 1.34% | — | 7.54% | 11.25% | 7.25% | 12.92% | 16.20% | 8.51% | 5.97% | 5.32% | -16.75% | 4.96% |
| Dec 31, 2010 | -43.74% | — | 10.64% | 9.98% | 8.07% | 16.35% | 25.03% | 12.96% | 0.81% | 4.23% | -9.59% | 4.85% |
| Dec 31, 2009 | -32.84% | — | 11.62% | 34.22% | 5.88% | 15.76% | 27.18% | 12.95% | 11.51% | 4.05% | -9.15% | 3.93% |
| Dec 31, 2008 | -46.90% | — | 11.51% | 17.76% | 7.53% | -7.09% | 28.65% | 15.25% | 16.54% | 7.29% | -12.34% | 4.71% |
| Dec 31, 2007 | -65.05% | — | 9.14% | 8.27% | 7.84% | 11.02% | 27.68% | 13.06% | 6.77% | 7.07% | -11.28% | 3.59% |
| Dec 31, 2006 | -22.45% | — | 8.73% | 6.20% | 8.72% | 12.13% | -29.12% | 15.67% | 9.95% | 16.84% | -17.49% | 0.79% |
| Dec 31, 2005 | -37.05% | — | 12.54% | 10.66% | 9.80% | 8.05% | 21.62% | 17.94% | 10.33% | 6.88% | -22.54% | 5.25% |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Vertex Pharmaceuticals Inc., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2025 | 15.42% | 9.28% |
| Dec 31, 2024 | -2.38% | 5.30% |
| Dec 31, 2023 | 15.92% | 7.25% |
| Dec 31, 2022 | 18.30% | 10.67% |
| Dec 31, 2021 | 17.44% | 10.42% |
| Dec 31, 2020 | 23.07% | 5.45% |
| Dec 31, 2019 | 14.15% | 9.02% |
| Dec 31, 2018 | 33.57% | 8.97% |
| Dec 31, 2017 | 7.43% | 5.28% |
| Dec 31, 2016 | -3.87% | 8.61% |
| Dec 31, 2015 | -22.26% | 8.93% |
| Dec 31, 2014 | -31.63% | 9.45% |
| Dec 31, 2013 | -19.19% | 9.46% |
| Dec 31, 2012 | -3.88% | 8.30% |
| Dec 31, 2011 | 1.34% | 7.30% |
| Dec 31, 2010 | -43.74% | 7.07% |
| Dec 31, 2009 | -32.84% | 10.02% |
| Dec 31, 2008 | -46.90% | 10.37% |
| Dec 31, 2007 | -65.05% | 8.86% |
| Dec 31, 2006 | -22.45% | 11.91% |
| Dec 31, 2005 | -37.05% | 10.42% |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Vertex Pharmaceuticals Inc., ROA, long-term trends, comparison to industry (health care)
| Vertex Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Dec 31, 2025 | 15.42% | 7.89% |
| Dec 31, 2024 | -2.38% | 5.73% |
| Dec 31, 2023 | 15.92% | 7.19% |
| Dec 31, 2022 | 18.30% | 9.66% |
| Dec 31, 2021 | 17.44% | 9.46% |
| Dec 31, 2020 | 23.07% | 5.81% |
| Dec 31, 2019 | 14.15% | 8.32% |
| Dec 31, 2018 | 33.57% | 7.90% |
| Dec 31, 2017 | 7.43% | 5.19% |
| Dec 31, 2016 | -3.87% | 7.31% |
| Dec 31, 2015 | -22.26% | 7.71% |
| Dec 31, 2014 | -31.63% | 8.59% |
| Dec 31, 2013 | -19.19% | 8.76% |
| Dec 31, 2012 | -3.88% | 8.09% |
| Dec 31, 2011 | 1.34% | 7.36% |
| Dec 31, 2010 | -43.74% | 7.24% |
| Dec 31, 2009 | -32.84% | 9.73% |
| Dec 31, 2008 | -46.90% | 9.50% |
| Dec 31, 2007 | -65.05% | 8.88% |
| Dec 31, 2006 | -22.45% | 10.52% |
| Dec 31, 2005 | -37.05% | 9.67% |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).